Cargando…
Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19
The differing roles of the pentameric (p) and monomeric (m) C-reactive protein (CRP) isoforms in viral diseases are not fully understood, which was apparent during the COVID-19 pandemic regarding the clinical course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Herein, w...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505432/ https://www.ncbi.nlm.nih.gov/pubmed/37724104 http://dx.doi.org/10.3389/fimmu.2023.1259005 |
_version_ | 1785106915852812288 |
---|---|
author | Hopkins, Francis R. Nordgren, Johan Fernandez-Botran, Rafael Enocsson, Helena Govender, Melissa Svanberg, Cecilia Svensson, Lennart Hagbom, Marie Nilsdotter-Augustinsson, Åsa Nyström, Sofia Sjöwall, Christopher Sjöwall, Johanna Larsson, Marie |
author_facet | Hopkins, Francis R. Nordgren, Johan Fernandez-Botran, Rafael Enocsson, Helena Govender, Melissa Svanberg, Cecilia Svensson, Lennart Hagbom, Marie Nilsdotter-Augustinsson, Åsa Nyström, Sofia Sjöwall, Christopher Sjöwall, Johanna Larsson, Marie |
author_sort | Hopkins, Francis R. |
collection | PubMed |
description | The differing roles of the pentameric (p) and monomeric (m) C-reactive protein (CRP) isoforms in viral diseases are not fully understood, which was apparent during the COVID-19 pandemic regarding the clinical course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Herein, we investigated the predictive value of the pCRP and mCRP isoforms for COVID-19 severity in hospitalized patients and evaluated how the levels of the protein isoforms changed over time during and after acute illness. This study utilized samples from a well-characterized cohort of Swedish patients with SARS-CoV-2 infection, the majority of whom had known risk factors for severe COVID-19 and required hospitalization. The levels of pCRP were significantly raised in patients with severe COVID-19 and in contrast to mCRP the levels were significantly associated with disease severity. Additionally, the pCRP levels remained elevated for at least six weeks post inclusion, which was longer compared to the two weeks for mCRP. Our data indicates a low level of inflammation lasting for at least six weeks following COVID-19, which might indicate that the disease has an adverse effect on the immune system even after the viral infection is resolved. It is also clear that the current standard method of testing pCRP levels upon hospitalization is a useful marker for predicting disease severity and mCRP testing would not add any clinical relevance for patients with COVID-19. |
format | Online Article Text |
id | pubmed-10505432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105054322023-09-18 Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19 Hopkins, Francis R. Nordgren, Johan Fernandez-Botran, Rafael Enocsson, Helena Govender, Melissa Svanberg, Cecilia Svensson, Lennart Hagbom, Marie Nilsdotter-Augustinsson, Åsa Nyström, Sofia Sjöwall, Christopher Sjöwall, Johanna Larsson, Marie Front Immunol Immunology The differing roles of the pentameric (p) and monomeric (m) C-reactive protein (CRP) isoforms in viral diseases are not fully understood, which was apparent during the COVID-19 pandemic regarding the clinical course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Herein, we investigated the predictive value of the pCRP and mCRP isoforms for COVID-19 severity in hospitalized patients and evaluated how the levels of the protein isoforms changed over time during and after acute illness. This study utilized samples from a well-characterized cohort of Swedish patients with SARS-CoV-2 infection, the majority of whom had known risk factors for severe COVID-19 and required hospitalization. The levels of pCRP were significantly raised in patients with severe COVID-19 and in contrast to mCRP the levels were significantly associated with disease severity. Additionally, the pCRP levels remained elevated for at least six weeks post inclusion, which was longer compared to the two weeks for mCRP. Our data indicates a low level of inflammation lasting for at least six weeks following COVID-19, which might indicate that the disease has an adverse effect on the immune system even after the viral infection is resolved. It is also clear that the current standard method of testing pCRP levels upon hospitalization is a useful marker for predicting disease severity and mCRP testing would not add any clinical relevance for patients with COVID-19. Frontiers Media S.A. 2023-09-01 /pmc/articles/PMC10505432/ /pubmed/37724104 http://dx.doi.org/10.3389/fimmu.2023.1259005 Text en Copyright © 2023 Hopkins, Nordgren, Fernandez-Botran, Enocsson, Govender, Svanberg, Svensson, Hagbom, Nilsdotter-Augustinsson, Nyström, Sjöwall, Sjöwall and Larsson https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Hopkins, Francis R. Nordgren, Johan Fernandez-Botran, Rafael Enocsson, Helena Govender, Melissa Svanberg, Cecilia Svensson, Lennart Hagbom, Marie Nilsdotter-Augustinsson, Åsa Nyström, Sofia Sjöwall, Christopher Sjöwall, Johanna Larsson, Marie Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19 |
title | Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19 |
title_full | Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19 |
title_fullStr | Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19 |
title_full_unstemmed | Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19 |
title_short | Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19 |
title_sort | pentameric c-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric crp in hospitalized patients with covid-19 |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505432/ https://www.ncbi.nlm.nih.gov/pubmed/37724104 http://dx.doi.org/10.3389/fimmu.2023.1259005 |
work_keys_str_mv | AT hopkinsfrancisr pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 AT nordgrenjohan pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 AT fernandezbotranrafael pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 AT enocssonhelena pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 AT govendermelissa pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 AT svanbergcecilia pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 AT svenssonlennart pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 AT hagbommarie pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 AT nilsdotteraugustinssonasa pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 AT nystromsofia pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 AT sjowallchristopher pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 AT sjowalljohanna pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 AT larssonmarie pentamericcreactiveproteinisabetterprognosticbiomarkerandremainselevatedforlongerthanmonomericcrpinhospitalizedpatientswithcovid19 |